Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Complementary Therapies Availability Poses Threat To Controlled Liver Trials

This article was originally published in The Tan Sheet

Executive Summary

Widespread use of alternative medicines for chronic liver disease will complicate randomized, controlled trials of those substances, former NIH Office of Alternative Medicine Director Wayne Jonas, MD, told a National Institutes of Health workshop on "Complementary and Alternative Medicine in Chronic Liver Disease" Aug. 23.

You may also be interested in...

Pilot Surveillance Of Herbals, Liver Toxicity Suggested By CDC Official

The creation of pilot surveillance programs to track the role of herbals and dietary supplements in unexplained episodes of hepatotoxicity was proposed by a Centers for Disease Control & Prevention epidemiologist at a symposium on complementary and alternative medicine in chronic liver disease. The symposium was held at the National Institutes of Health in Bethesda, Md. Aug. 24.

NIH St. John's wort trial

NIH clinical trial studying St. John's wort's efficacy in treating depression has enrolled about one-fourth of the expected 330 patients. The study, led by principle investigator Jonathan Davidson, MD, Duke University, is being funded by NIH's National Center for Complementary & Alternative Medicine, National Institute of Mental Health and Office of Dietary Supplements. Recruitment was delayed due to a problem with Duke's Review Board research review procedures ("The Tan Sheet" May 17, In Brief)

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts